Poster - #VH-77682 - Keywords: Neuroinflamation, miRNA, SUD, Affective Disorders

Development of Therapies to Target Neuroinflammation

Authors: Alena Espinosa Alvernia1, Aliya Z. Ali1,3, Jilyan Hustic1,2, Samantha J. CiFuentes1, Dunia Deif1,4, Valerie Bargan1,2, Madison Higgins1,2, Antonio Castro1 ,Olivia Pesci1,2, Ashley Innes1, Harry W. Kestler1, Hannah Newsome1
Lorain County Community College1, Early College High School2, Avon High School3, Lorain High School4

ABSTRACT:
Psychiatric disorders are biologically heterogeneous and often mischaracterized by subjective diagnostic frameworks that overlook underlying molecular drivers. This study investigates the role of microRNAs (miRNAs) in modulating neuropsychiatric phenotypes, with a focus on identifying biomarker signatures associated with self- medicating behaviors, neuroinflammation, and treatment response. Grounded in the self-medicating hypothesis, we propose that dysregulated miRNA expression may contribute to both symptom severity and the compensatory use of psychoactive substances. To explore this, we established a small-scale biobank incorporating saliva samples, SNP genotyping, and behavioral data from individuals with diagnosed or suspected psychiatric conditions, including ADHD, substance use disorders, and affective disorders. Repeated saliva samples were collected longitudinally following first-time administration of psychiatric medications (e.g., stimulants), alongside detailed environmental, behavioral, and familial history. We conducted multivariate biomarker analysis, integrating miRNA expression profiles with SNPs in neuropsychiatric and inflammatory pathways, patient-reported experiences, and clinical outcomes. Preliminary findings suggest individual-specific miRNA signatures may correlate with behavioral traits, drug response, and inflammatory status, supporting a model in which miRNAs mediate gene-environment interactions relevant to psychiatric vulnerability and resilience. This work highlights the potential of miRNA-based diagnostics and paves the way for personalized psychiatric interventions rooted in molecular precision.